The month-long bioavailability of the antibody is clinically useful for chronic diseases like Multiple Sclerosis, but for leukemia treatment presence of the inhibitor only during the chemotherapy is likely sufficient and, because of the above-said risks of PML, probably preferable. Here, PML is linked to leukemia.